Dr Johann S. de Bono, of The Institute of Cancer Research in London, reviews key studies on prostate cancer presented at the 2020 ESMO Virtual Congress, including the phase 3 PROfound trial, which led to the approval of the PARP inhibitor olaparib for patients with metastatic prostate cancer.
He also discusses updated results of the STAMPEDE phase 3 trial of abiraterone plus ADT and the IPATential150 study of the AKT inhibitor ipatasertib plus abiraterone for patients with advanced prostate cancer.
Finally, he reviews several emerging new immunotherapies for prostate cancer that are showing promise in early clinical trials.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author’s own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Prostate Cancer Highlights From ESMO 2020 – Medscape – Oct 12, 2020.